Evidence map›Paper›PMID 40840122›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Network pharmacology and experimental validation reveal that betulin alleviates 5-fluorouracil-induced intestinal injury by inhibiting intestinal senescence and enhances antitumor efficacy.

Zhi-Wei Wang, Xiao-Jian Wu, Qian-Long Dai, Zhen-Lin Liu, Cheng-Gang Zhao, Wei Lian, Yue Zhao, Li-Hua Li, Xiao-Bo Wang

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Mechanisms and therapeutic potential of therapy-induced cellular senescence in radiotherapy- and chemotherapy-related alimentary tract mucositis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhi-Wei WangSchool of Basic Medicine, Dali University, Dali, Yunnan, China.
Xiao-Jian WuMicrobiology Research Institute, Guangxi Academy of Agricultural Science, Nanning, Guangxi Province, China.
Qian-Long DaiSchool of Basic Medicine, Dali University, Dali, Yunnan, China.
Zhen-Lin LiuSchool of Basic Medicine, Dali University, Dali, Yunnan, China.
Cheng-Gang ZhaoMicrobiology Research Institute, Guangxi Academy of Agricultural Science, Nanning, Guangxi Province, China.
Wei LianSchool of Basic Medicine, Dali University, Dali, Yunnan, China.
Yue ZhaoSchool of Basic Medicine, Dali University, Dali, Yunnan, China. Electronic address: zy19860908@yeah.net.
Li-Hua LiDepartment of Geriatrics, The First Affiliated Hospital of Dali University, Dali, Yunnan, China. Electronic address: lilihuayncn@163.com.
Xiao-Bo WangSchool of Basic Medicine, Dali University, Dali, Yunnan, China. Electronic address: wxb4320062@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Fluorouracil (5-FU) remains the first-line chemotherapeutic agent for colorectal cancer. Although 5-FU significantly improves patient survival, its severe gastrointestinal toxicity-particularly intestinal injury and diarrhea-impairs treatment adherence and patient quality of life, often leading to therapeutic failure. Thus, effective interventions to prevent or mitigate these adverse effects are urgently needed. Betulin (BET), a natural pentacyclic triterpenoid derived primarily from birch bark, exhibits various biological activities, including anti-inflammatory, antioxidant, antiviral, and antitumor effects. Its anti-inflammatory and antioxidant properties suggest betulin (BET) as a promising candidate for alleviating chemotherapy-induced tissue damage. However, its impact on 5-FU-induced intestinal injury remains unclear. The findings of this study revealed that 5-FU led to significant intestinal injury by promoting cellular senescence and exacerbating the inflammatory response. BET mitigates these effects by decreasing senescence-associated β-galactosidase activity and downregulating key senescence markers such as p53, p21, and p16. Moreover, BET modulates senescence-associated secretory phenotype factors, thereby reversing the proinflammatory microenvironment elicited by 5-FU. Integrating network pharmacology, Mendelian randomization, and experimental validation, we identified the mechanistic target of rapamycin/mitogen-activated protein kinase signaling pathway as a pivotal mediator of BET's protective effects against 5-FU-induced intestinal injury. In conclusion, our study reveals that 5-FU-induced intestinal damage is driven by cellular senescence, which BET effectively ameliorates through suppression of senescence and inflammation. These findings provide a novel framework for targeting antisenescence strategies to alleviate chemotherapy-associated intestinal toxicity. SIGNIFICANCE STATEMENT: This study identifies betulin as a novel agent that alleviates 5-fluorouracil-induced intestinal injury by inhibiting cellular senescence and inflammation via the mechanistic target of rapamycin/mitogen-activated protein kinase pathways. These findings highlight antisenescence as a promising therapeutic strategy to mitigate chemotherapy-induced gastrointestinal toxicity.

Indexed as

Antineoplastic AgentsCellular SenescenceFluorouracilIntestinesNetwork PharmacologyTriterpenesAnimalsAntimetabolites, AntineoplasticBetulinic AcidHumansMaleMiceMice, Inbred C57BLAntimetabolites, AntineoplasticAntineoplastic AgentsbetulinBetulinic AcidFluorouracilTriterpenes5-FluorouracilBetulinCellular senescenceIntestinal damageNetworkpharmacology

Identifiers

PMID40840122
PMCPMC12597644

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.